Literature DB >> 24326630

Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.

Sun-pyo Hong1, Tae Soo Noh, Seung-Hwan Moon, Young Seok Cho, Eun Jeong Lee, Joon Young Choi, Byung-Tae Kim, Kyung-Han Lee.   

Abstract

BACKGROUND: Subjects with fatty liver disease (FLD) can show increased hepatic 2-deoxy-2-((18)F)fluoro-D-glucose (FDG) uptake, but the role of hepatic inflammation has not been explored. AIMS: We investigated whether hepatic inflammatory response, as implicated by elevated serum markers, is associated with increased liver FDG uptake in FLD.
METHODS: Liver sonography and FDG positron emission tomography was performed in 331 asymptomatic men with nonalcoholic FLD (NAFLD), 122 with alcoholic FLD (AFLD), and 349 controls. Mean standard uptake value (SUV) of liver FDG uptake was compared to cardiac risk factors and serum markers of liver injury.
RESULTS: Hepatic FDG mean SUV was increased in NAFLD (2.40 ± 0.25) and AFLD groups (2.44 ± 0.25) compared to controls (2.28 ± 0.26; both P < 0.001). Both FLD groups also had higher serum γ-glutamylranspeptidase (GGT), triglyceride (TG), hepatic transaminases, and LDL. High GGT and TG levels were independent determinants of increased FDG uptake for both FLD groups. Hepatic mean SUV significantly increased with high compared to low GGT for NAFLD (2.48 ± 0.28 vs. 2.37 ± 0.24), AFLD (2.51 ± 0.27 vs. 2.39 ± 0.23), and control groups (2.39 ± 0.22 vs. 2.26 ± 0.26). High TG increased hepatic mean SUV in AFLD and control groups. Furthermore, serum GGT and TG levels significantly correlated to hepatic mean SUV in all three groups.
CONCLUSIONS: Hepatic FDG uptake is closely associated with elevated TG and GGT regardless of the presence of FLD. Thus, inflammation response may play a major role in increased hepatic glucose uptake.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24326630     DOI: 10.1007/s10620-013-2957-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome.

Authors:  G Marchesini; S Avagnina; E G Barantani; A M Ciccarone; F Corica; E Dall'Aglio; R Dalle Grave; P S Morpurgo; F Tomasi; E Vitacolonna
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.

Authors:  Ronald Borra; Riika Lautamäki; Riita Parkkola; Markku Komu; Paul E Sijens; Kirsti Hällsten; Jörgen Bergman; Patricia Iozzo; Pirjo Nuutila
Journal:  Metabolism       Date:  2008-10       Impact factor: 8.694

3.  Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT.

Authors:  Gad Abikhzer; Yazan Z Alabed; Laurent Azoulay; Jonathan Assayag; Chris Rush
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

Review 4.  FDG PET of infection and inflammation.

Authors:  Charito Love; Maria B Tomas; Gene G Tronco; Christopher J Palestro
Journal:  Radiographics       Date:  2005 Sep-Oct       Impact factor: 5.333

Review 5.  (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.

Authors:  Shankar Vallabhajosula
Journal:  Semin Nucl Med       Date:  2007-11       Impact factor: 4.446

6.  Hepatic expression of gamma-glutamyltranspeptidase in the human liver of patients with alcoholic liver disease.

Authors:  Makoto Irie; Norihisa Suzuki; Tetsuro Sohda; Akira Anan; Kaoru Iwata; Yasuaki Takeyama; Hiroshi Watanabe; Peter Fischer; Jürgen E Scherberich; Shotaro Sakisaka
Journal:  Hepatol Res       Date:  2007-11       Impact factor: 4.288

7.  Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.

Authors:  Veysel Tahan; Billur Canbakan; Huriye Balci; Faysal Dane; Hakan Akin; Guray Can; Ibrahim Hatemi; Vakur Olgac; Abdullah Sonsuz; Gulsen Ozbay; Ibrahim Yurdakul; Hakan Senturk
Journal:  Hepatogastroenterology       Date:  2008 Jul-Aug

8.  Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis.

Authors:  Linda E Muñoz; Paula Cordero; Liliana Torres; Alma Y Sauceda; Juan P Flores; Jose J Segura
Journal:  Ann Hepatol       Date:  2009 Apr-Jun       Impact factor: 2.400

9.  Evaluation of hepatic metabolic activity in non-alcoholic fatty livers on 18FDG PET/CT.

Authors:  Z Dostbil; E Varoğlu; M Serdengeçti; B Kaya; H Onder; O Sari
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2012-05-31       Impact factor: 1.359

Review 10.  Metabolic syndrome and NASH.

Authors:  Giulio Marchesini; Rebecca Marzocchi
Journal:  Clin Liver Dis       Date:  2007-02       Impact factor: 6.126

View more
  4 in total

1.  Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease.

Authors:  Seung Hwan Moon; Sun-Pyo Hong; Young Seok Cho; Tae Soo Noh; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  J Nucl Cardiol       Date:  2015-10-28       Impact factor: 5.952

2.  Glucose induces sensitivity to oxygen deprivation and modulates insulin/IGF-1 signaling and lipid biosynthesis in Caenorhabditis elegans.

Authors:  Anastacia M Garcia; Mary L Ladage; Dennis R Dumesnil; Khadiza Zaman; Vladimir Shulaev; Rajeev K Azad; Pamela A Padilla
Journal:  Genetics       Date:  2015-03-10       Impact factor: 4.562

3.  Hepatic FDG uptake in patients with NAFLD: An important prognostic factor for cardio-cerebrovascular events?

Authors:  Aukelien C Dimitriu-Leen; Arthur J H A Scholte
Journal:  J Nucl Cardiol       Date:  2016-01-04       Impact factor: 5.952

4.  Hepatic glucose utilization in hepatic steatosis and obesity.

Authors:  Georgia Keramida; James Hunter; Adrien Michael Peters
Journal:  Biosci Rep       Date:  2016-11-03       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.